Piotr Rutkowski, MD, PhD, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, discusses the potential use of electrochemotherapy in various types of melanoma. Electrochemotherapy is a relatively easy procedure and has a high local response rate, although it has a limited activity in larger tumors and irradiated or fibrotic tissue. In Europe, electrochemotherapy is currently used predominantly in metastatic skin cancer, including in-transit metastatic melanoma for palliative care. Dr. Rutkowski describes novel applications of electrochemotherapy and its potential use in combination with immune checkpoint inhibitors for metastatic melanoma. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Piotr Rutkowski, MD, PhD has received honoraria for lectures and Advisory Boards from MSD, BMS, Novartis, Pierre Fabre, Sanofi, Merck and Blueprint Medicines.